Journal of the Korean neurological association (대한신경과학회지)

Korean Neurological Association (대한신경과학회)
권호 표지
DOI QR코드

DOI QR Code

Rituximab Treatment for Polyneuropathy Induced by an Immune Checkpoint Inhibitor

Immune Checkpoint Inhibitor에 의한 다발신경병의 Rituximab 치료

  • Shin, Hye-Rim (Department of Neurology, Seoul National University Hospital) ;
  • Kang, Dong-Wan (Department of Neurology, Seoul National University Hospital) ;
  • Kim, Eun Young (Department of Neurology, Seoul National University Hospital) ;
  • Kim, Tae Min (Department of Internal Medicine, Seoul National University Hospital) ;
  • Lee, Soon-Tae (Department of Neurology, Seoul National University Hospital)
  • 신혜림 (서울대학교병원 신경과) ;
  • 강동완 (서울대학교병원 신경과) ;
  • 김은영 (서울대학교병원 신경과) ;
  • 김태민 (서울대학교병원 내과) ;
  • 이순태 (서울대학교병원 신경과)
  • Received : 2018.06.21
  • Accepted : 2018.07.23
  • Published : 2018.11.30
⟨ Previous Next ⟩

Abstract

Immune checkpoint inhibitor is associated with variety of immune-related adverse events. We present a case of polyneuropathy induced by immune checkpoint inhibitor, which was refractory to steroid and immunoglobulin. While high-dose steroid and immunoglobulin were not effective, we tried rituximab which is effective in other immune-mediated polyneuropathy. After rituximab treatment, patient's clinical symptom and nerve conduction study finding was markedly improved. We suggest rituximab might be effective in polyneuropathy induced by immune checkpoint inhibitor.

Keywords

References

  1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of an ti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454. https://doi.org/10.1056/NEJMoa1200690
  2. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139-148. https://doi.org/10.1016/j.ejca.2015.11.016
  3. Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract Neurol 2013;13:278-280. https://doi.org/10.1136/practneurol-2012-000447
  4. Motamed-Gorji N, Matin N, Tabatabaie O, Pavone P, Romano C, Falsaperla R, et al. Biological drugs in Guillain-Barre syndrome: an update. Curr Neuropharmacol 2017;15:938-950.
  5. Sakai K, Mochizuki H, Mochida K, Shiomi K, Amano M, Nakazato M. A case of nivolumab-induced severe mononeuropathy multiplex and rhabdomyolysis. Case Rep Med 2017;2017:1093858.
  6. Gu Y, Menzies AM, Long GV, Fernando SL, Herkes G. Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci 2017;45:14-17. https://doi.org/10.1016/j.jocn.2017.07.014
  7. Fukumoto Y, Kuwahara M, Kawai S, Nakahama K, Kusunoki S. Acute demyelinating polyneuropathy induced by nivolumab. J Neurol Neurosurg Psychiatry 2018;89:435-437. https://doi.org/10.1136/jnnp-2017-316510
  8. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-2697. https://doi.org/10.1200/JCO.2012.41.6750
  9. Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Avila AL, Le DT, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016;73:928-933. https://doi.org/10.1001/jamaneurol.2016.1399
  10. Ito M, Fujiwara S, Fujimoto D, Mori R, Yoshimura H, Hata A, et al. Rituximab for nivolumab plus ipilimumab - induced encephalitis in a small-cell lung cancer patient. Ann Oncol 2017;28:2318-2319. https://doi.org/10.1093/annonc/mdx252